Arbutus Biopharma (ABUS) Interest Expenses (2010 - 2026)

Arbutus Biopharma (ABUS) has reported Interest Expenses for 17 consecutive years, with $23000.0 the latest figure, recorded in Q1 2026.

• Quarterly Interest Expenses fell 17.86% year-over-year to $23000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $23000.0 (down 82.44% YoY) and the FY2025 annual result came in at $181.4 million, up 3.4% from the prior year.
• Interest Expenses retreated to $23000.0 in Q1 2026 per ABUS's latest filing, from $555000.0 in the prior quarter.
• Over the last five years, Interest Expenses for ABUS reached as high as $555000.0 in Q4 2025 and fell as low as -$776000.0 in Q4 2022.
• A 5-year average of $122411.8 and a median of $46000.0 in 2023 frame the typical range for Interest Expenses.
• Annual changes were most pronounced in 2023 — Interest Expenses slumped 89.28% — and 2025, when it soared 1750.0%.
• Year by year, Interest Expenses stood at -$776000.0 in 2022, then surged by 105.67% to $44000.0 in 2023, then slumped by 31.82% to $30000.0 in 2024, then surged by 1750.0% to $555000.0 in 2025, then plunged by 95.86% to $23000.0 in 2026.
• According to Business Quant data, Interest Expenses over the past three periods registered $23000.0, $555000.0, and $23000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.